S&P 500
(1.03%) 5 180.74 points
Dow Jones
(0.46%) 38 852 points
Nasdaq
(1.19%) 16 349 points
Oil
(0.54%) $78.90
Gas
(-1.28%) $2.17
Gold
(0.24%) $2 336.70
Silver
(0.17%) $27.66
Platinum
(0.39%) $968.70
USD/EUR
(-0.02%) $0.928
USD/NOK
(-0.08%) $10.82
USD/GBP
(-0.05%) $0.796
USD/RUB
(-0.02%) $91.33

Aktualne aktualizacje dla Fate Therapeutics Inc [FATE]

Giełda: NASDAQ Sektor: Healthcare Branża: Biotechnology
Upcoming Earnings Alert

Quarter results tomorrow
(bmo 2024-05-08)

Expected move: +/- 7.59%

BUY
87.50%
return 6.93%
SELL
37.50%
return 5.76%
Ostatnio aktualizowano6 geg. 2024 @ 23:00

3.94% $ 4.22

KUPNO 118344 min ago

@ $6.43

Wydano: 14 vas. 2024 @ 22:38


Zwrot: -34.37%


Poprzedni sygnał: vas. 14 - 20:20


Poprzedni sygnał: Sprzedaż


Zwrot: -1.30 %

Live Chart Being Loaded With Signals

Commentary (6 geg. 2024 @ 23:00):

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide...

Stats
Dzisiejszy wolumen 2.22M
Średni wolumen 2.62M
Kapitalizacja rynkowa 480.31M
EPS $0 ( 2024-05-01 )
Następna data zysków ( $-0.480 ) 2024-05-08
Last Dividend $0 ( N/A )
Next Dividend $0 ( N/A )
P/E -2.57
ATR14 $0.00800 (0.19%)
Insider Trading
Date Person Action Amount type
2024-03-21 Redmile Group, Llc Buy 3 636 364 Pre-Funded Warrants to Purchase Common Stock
2024-03-04 Dulac Edward J Iii Sell 2 447 Common Stock
2024-02-01 Wolchko J Scott Buy 500 000 Stock Option (Right to Buy)
2024-02-01 Tahl Cindy Buy 425 000 Stock Option (Right to Buy)
2024-02-01 Dulac Edward J Iii Buy 425 000 Stock Option (Right to Buy)
INSIDER POWER
40.72
Last 99 transactions
Buy: 17 254 718 | Sell: 8 388 589

Wolumen Korelacja

Długi: 0.55 (weak)
Krótki: 0.96 (very strong)
Signal:(71.628) Expect same movement, but be aware

Fate Therapeutics Inc Korelacja

10 Najbardziej pozytywne korelacje
STRC0.974
ONCS0.971
WISA0.97
TTCF0.969
IMRX0.968
LUMO0.964
GROM0.961
VIRX0.957
MEDS0.956
IMCC0.956
10 Najbardziej negatywne korelacje
NWFL-0.96
IBEX-0.95
MNKD-0.947
PWOD-0.942
LRFC-0.935
HZNP-0.934
PDD-0.931
XOMAO-0.931
ISIG-0.93
IMMR-0.93

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Fate Therapeutics Inc Korelacja - Waluta/Towar

The country flag 0.33
( neutral )
The country flag -0.13
( neutral )
The country flag 0.00
( neutral )
The country flag 0.88
( strong )
The country flag 0.51
( weak )
The country flag -0.04
( neutral )

Fate Therapeutics Inc Finanse

Annual 2023
Przychody: $63.53M
Zysk brutto: $45.25M (71.22 %)
EPS: $-1.640
FY 2023
Przychody: $63.53M
Zysk brutto: $45.25M (71.22 %)
EPS: $-1.640
FY 2022
Przychody: $96.30M
Zysk brutto: $82.54M (85.71 %)
EPS: $-2.63
FY 2021
Przychody: $55.85M
Zysk brutto: $55.85M (100.00 %)
EPS: $-2.24

Financial Reports:

No articles found.

Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

O Sygnały na żywo

Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.

Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej